West Nile virus (WNV) Envelope DIII domain

Recombinant West Nile virus (WNV) Envelope Domain III protein (aa 1–108), expressed in E. coli with a C-terminal His-tag and purified from cell pellet by immobilized metal affinity and ion exchange

PRODUCT DETAILS – West Nile virus (WNV) Envelope DIII domain

• Accession: 2P5P_A
• Strain/Isolate: NY-99
• Tag: His-Tag, C-Terminus
• Expressed in E. coli
• Presented as liquid in 20 mM potassium carbonate, pH 9.6

BACKGROUND

West Nile virus (WNV) envelope domain III (DIII) is a well-characterized region of the E glycoprotein involved in host-cell attachment and antibody recognition (Pletnev et al., 2005; Nybakken et al., 2005). Recombinant DIII has been used in studies of viral entry and shown to inhibit WNV infection in experimental systems, supporting its value as a defined antigen for research applications (Pletnev et al., 2005). Because this domain contains key neutralizing epitopes, it is widely used to study virus–host interactions and humoral immune responses (Nybakken et al., 2005).

WNV DIII has also been explored in diagnostic research because flavivirus serology is often complicated by cross-reactivity, and DIII-based assays have been evaluated to support more specific serological diagnosis of WNV infection (Maciel et al., 2003; Figueiredo et al., 2012). In vaccine research, DIII has been used as a defined research antigen to assess immunogenicity and protective responses in preclinical studies, including work showing that DIII can induce neutralizing antibodies and protection after challenge (Chu et al., 2007; Sereesongsaeng et al., 2011). Together, these studies support WNV DIII as a useful reagent for assay development and vaccine research focused on flavivirus immunity.

REFERENCES

Pletnev SV, et al. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. Journal of Virology. 2005.

Nybakken GE, et al. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature. 2005.

Maciel M, et al. Use of a recombinant envelope protein subunit antigen for specific serological diagnosis of West Nile virus infection. Journal of Clinical Microbiology. 2003.

Figueiredo LT, et al. Production and diagnostic application of recombinant domain III of West Nile virus envelope protein. Revista da Sociedade Brasileira de Medicina Tropical. 2012.

Chu JJH, et al. Immunization of Flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. Journal of Immunology. 2007.

Sereesongsaeng et al. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII. Vaccine. 2011.